Revolo Biotherapeutics completes clinical trial of ‘1104 for allergic disease
Great Shelford-based Revolo Biotherapeutics has completed its phase 2a clinical trial of an immune-resetting drug, known as ‘1104, for allergic disease.
The company expects top-line data from the study in the second quarter of the year.
Revolo, which has offices at Windsor House in Station Court, as well as a US base in New Orleans, is developing therapies to reset the immune system to enable the long-term remission of patients with autoimmune and allergic conditions.
CEO Jonathan Rigby said: “We are pleased to have reached this relevant milestone and look forward to receiving data from the study in the near future.
“Building on the promising pre-clinical data that has showcased ‘1104’s long-lasting and allergen-agnostic anti-inflammatory effects, we are excited by this clinical progress. We look forward to initiating a food allergy clinical study where there is a very large unmet need as a next step in the development of ‘1104.”
The randomised, double-blind, placebo-controlled, parallel-group study was designed to evaluate the safety and efficacy of ‘1104 in 60 patients with moderate to severe allergy.
Participants received six doses of either ‘1104 or a placebo over six visits within the 12-week period.
The investigational drug is a first-in-class peptide derived from a natural immune-regulatory protein called mTB Chaperonin 60.1 that is involved in resetting the immune system.
Revolo Bio has advanced ‘1104 through two Phase 2a trials: one in patients with eosinophilic esophagitis (EoE) and one in patients with allergen sensitivity, while exploring its potential for other allergic diseases.